logo
Sign in

HOPHF Stock Price, Chart, Stats & News

Hemogenyx Pharmaceuticals Plc
Save

Hemogenyx Pharmaceuticals Plc (HOPHF) does not currently pay a dividend.

15.84M
Market cap
Current P/E
Forward P/E

HOPHF chart

1M
3M
1Y
5Y
Loading chart...

About

Health care
Sector
Biotechnology
Industry

Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome.

Similar securities

Based on sector and market capitalization

Report issue